Home/Filings/4/0001193125-26-021378
4//SEC Filing

Pizzie Nick 4

Accession 0001193125-26-021378

CIK 0001579428other

Filed

Jan 22, 7:00 PM ET

Accepted

Jan 23, 7:00 PM ET

Size

9.8 KB

Accession

0001193125-26-021378

Research Summary

AI-generated summary of this filing

Updated

Axsome (AXSM) CFO Pizzie Nick Sells Shares After Exercising Options

What Happened
Pizzie Nick, Chief Financial Officer of Axsome Therapeutics (AXSM), exercised 12,000 stock options at $3.50 per share (cost $42,000) and immediately sold 12,000 common shares in the open market for total gross proceeds of about $2,255,040 (weighted‑average sale price $187.92). The filing also reports a related derivative disposition at $0.00 that corresponds to the sale of the underlying shares from the option exercise.

Key Details

  • Transaction date: January 22, 2026; Form 4 filed January 23, 2026 (timely).
  • Option exercise: 12,000 shares @ $3.50 = $42,000 (Footnote F1: options held ~8 years; exercised before 10‑year expiration).
  • Sale: 12,000 shares @ weighted avg $187.92 = $2,255,040 (Footnote F4: sale prices ranged $185.09–$191.12).
  • Reported derivative disposition: 12,000 shares @ $0.00 — per footnote F3 this reflects the subsequent sale of the shares acquired on exercise.
  • Sale was made pursuant to a pre‑approved 10b5‑1 trading plan (Footnote F2).
  • Shares owned after the transactions: not specified in the provided excerpt.
  • Includes other holdings from ESPP and custodial UTMA accounts (Footnotes F5, F6).

Context
This is a common pattern where an insider exercises long‑held options and immediately sells the resulting shares under a pre‑arranged plan (often called a cashless exercise plus systematic sale). The reported activity generated roughly $2.255M in gross proceeds versus $42k in option exercise cost (≈ $2.213M difference) before taxes and fees. The 10b5‑1 designation indicates the sale was made under a pre‑established plan rather than an ad hoc decision.

Insider Transaction Report

Form 4
Period: 2026-01-22
Pizzie Nick
Chief Financial Officer
Transactions
  • Exercise/Conversion

    Common Stock

    [F1][F2][F5]
    2026-01-22$3.50/sh+12,000$42,00054,588 total
  • Sale

    Common Stock

    [F2][F3][F4][F5]
    2026-01-22$187.92/sh12,000$2,255,04042,588 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    [F2]
    2026-01-2212,000105,000 total
    Exercise: $3.50From: 2019-05-16Exp: 2028-05-16Common Stock (12,000 underlying)
Holdings
  • Common Stock

    [F6]
    (indirect: See explanation 6 below.)
    488
Footnotes (6)
  • [F1]Represents an exercise of stock options which was held for 8 years and exercised prior to the 10-year expiration date of such options.
  • [F2]Such transaction was pursuant to a pre-approved 10b5-1 plan.
  • [F3]Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.
  • [F4]Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $185.09 and $191.12.
  • [F5]Includes the prior purchase of shares of common stock pursuant to the Issuer's Employee Stock Purchase Plan.
  • [F6]Represents additional shares indirectly beneficially owned by the reporting person as custodian for his children's UTMA accounts.
Signature
/s/ Nick Pizzie|2026-01-23

Documents

1 file

Issuer

Axsome Therapeutics, Inc.

CIK 0001579428

Entity typeother

Related Parties

1
  • filerCIK 0001742143

Filing Metadata

Form type
4
Filed
Jan 22, 7:00 PM ET
Accepted
Jan 23, 7:00 PM ET
Size
9.8 KB